Compare IBEX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | PBYI |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.0M | 413.3M |
| IPO Year | 2017 | 2011 |
| Metric | IBEX | PBYI |
|---|---|---|
| Price | $37.38 | $9.23 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 92.5K | ★ 296.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.26 | N/A |
| EPS | ★ 2.54 | 0.08 |
| Revenue | ★ $558,273,000.00 | $27,685,000.00 |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | ★ $14.42 | $114.50 |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $25.94 | $4.30 |
| 52 Week High | $42.99 | $9.51 |
| Indicator | IBEX | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 61.69 |
| Support Level | $36.51 | $7.44 |
| Resistance Level | $39.81 | $9.45 |
| Average True Range (ATR) | 1.13 | 0.36 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 91.83 | 78.64 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.